Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012

Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Leaky blood-brain barrier linked to Alzheimer's disease
Researchers using contrast-enhanced MRI have identified leakages in the blood-brain barrier (BBB) of people with early Alzheimer's disease (AD), according to a new study published online in the journal Radiology.

Vicious circle of platelets
They were published in the current issue of the renowned journal "Science Signaling". The scientists provide evidence for the first time that treatment of Alzheimer transgenic model mice with an anti-platelet drug leads to significantly reduced amyloid plaques in cerebral vessels.

Study paves way for new therapies in fight against calcium disorders
A study led by researchers at Georgia State University provides new insights into the molecular basis of human diseases resulting from mutations in the calcium-sensing receptor (CaSR), a protein found in cell membranes.

Ancient anti-inflammatory drug salicylic acid has cancer-fighting properties
Scientists from the Gladstone Institutes have identified a new pathway by which salicylic acid--a key compound in the nonsteroidal anti-inflammatory drugs aspirin and diflunisal--stops inflammation and cancer.

The deadly toxin acrolein has a useful biological role
Scientists from RIKEN in Japan have discovered that acrolein--a toxic substance produced in cells during times of oxidative stress--in fact may play a role in preventing the process of fibrillation, an abnormal clumping of peptides that has been associated with Alzheimer's disease and other neural diseases.

Researchers identify immune genes tied to common, deadly brain cancer
Researchers have identified a group of immune system genes that may play a role in how long people can live after developing a common type of brain cancer called glioblastoma multiforme, a tumor of the glial cells in the brain.

Can Alzheimer's disease-associated peptide fight bacterial infection?
Amyloid-ß is a sticky peptide notorious for forming destructive plaques in the brains of Alzheimer's disease patients, but a new study suggests that it may also serve a protective function as an antimicrobial peptide.

Human amyloid-beta acts as natural antibiotic in the brains of animal models
A new study from Massachusetts General Hospital (MGH) investigators provides additional evidence that amyloid-beta protein - which is deposited in the form of beta-amyloid plaques in the brains of patients with Alzheimer's disease - is a normal part of the innate immune system, the body's first-line defense against infection.

Progranulin and dementia -- a blood sample does not tell the full story!
Progranulin is a central protein in both neuronal survival and neurodegenerative diseases. It is thus not surprising that altered progranulin levels represent a universal theme shared across several common neurodegenerative diseases.

PET imaging with special tracer can detect and diagnose early Alzheimer's disease
The effort to find ways to detect and diagnose preclinical Alzheimer's disease (AD) has taken a big step forward with the use of positron emission tomography (PET), a "nuclear medicine" for imaging processes in the body, when PET is used with a special 'tracer' that binds to the amyloid plaques in the brain that are a characteristic cause of AD.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

The Alzheimer's Prevention & Treatment Diet

The Alzheimer's Prevention & Treatment Diet
by Richard S. Isaacson MD (Author), Christopher N. Ochner PhD (Author)


Alzheimer’s disease (AD) is a type of dementia that can be very hard on both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer’s disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer’s disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer’s Prevention & Treatment Diet outlines a cutting-edge nutritional...

Outsmarting Alzheimer's: What You Can Do to Reduce Your Risk

Outsmarting Alzheimer's: What You Can Do to Reduce Your Risk
by Kenneth S. Kosik MD (Author)


An easy-to-follow, research-based guide to the simple, low-cost choices that give the reader the power to reduce the risk of developing Alzheimer's disease and dementia; slow the progression of the disease; and mitigate symptoms and improve well-being.

Did you know that getting on the treadmill can help keep your brain sharp? Or that repeatedly staying up to catch the late show could increase the likelihood of being struck down by dementia? The dozens of choices you make over the course of any average day—ordering the curry versus the burger with fries, taking the stairs versus the elevator—all add up. Together with your family history, they establish your chances of getting Alzheimer’s years from now. No drugs or procedures can cure or even effectively treat Alzheimer’s...

Counseling People with Early-Stage Alzheimer's Disease: A Powerful Process of Transformation

Counseling People with Early-Stage Alzheimer's Disease: A Powerful Process of Transformation
by Robyn Yale L.C.S.W. (Author)


People with early dementia face enormous challenges in coping with their condition, yet they typically receive no personalized education or support following the diagnosis. Counseling empowers them to understand and come to terms with the illness while also learning to manage and make healthy adaptations to it. With the rapid increase in people diagnosed with early memory impairment and demand for better support services this groundbreaking new guide gives you essential tools to become an integral partner in a process that helps people adjust to the many changes in their lives.

Presenting an innovative new counseling framework designed around the unique problems and needs arising from dementia, Counseling People with Early-Stage Alzheimer s Disease guides the counselor and client...

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones
by Mary T Newport (Author)


Acting on new research showing that medium-chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease, author Dr. Mary T. Newport has demonstrated through her care for her husband that there is hope, relief, and perhaps a cure.

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease
by Joanne Koenig Coste (Author), Robert Butler (Foreword)


More than four million Americans suffer from Alzheimer’s, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between carepartners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the...

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)


Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

Losing My Mind: An Intimate Look at Life with Alzheimer's

Losing My Mind: An Intimate Look at Life with Alzheimer's
by Thomas DeBaggio (Author)


"We are foolish, those of us who think we can escape the traps of aging," writes Tom DeBaggio. "I was one of them, dreaming of a perfect and healthy old age....Now, at fifty-eight, I realize the foolishness of my dreams as I watch my brain self-destruct from Alzheimer's." Losing My Mind is DeBaggio's extraordinary account of his early onset Alzheimer's, a disease that "silently hollows the brain" and slowly "gobbles memory and destroys life." But with DeBaggio's curse came an unexpected blessing: the ability to chart the mechanics and musings of his failing mind.
Whether describing the happy days of his youth or lamenting over the burden his disease has placed upon his loved ones, DeBaggio manages to inspire the reader with his ability to function, to think, and ultimately to...

The Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life

The Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life
by Gary Small (Author), Gigi Vorgan (Author)


Want to keep Alzheimer’s at bay for years—ideally, forever? Prevention is the way, and this is the guide. Now in paperback and updated throughout, The Alzheimer’s Prevention Program is essential for everyone with a family history of Alzheimer’s, and for the 80 million baby boomers who worry whenever they forget someone’s name. It’s the book that shows how to strengthen memory and avoid everyday lapses. How to incorporate the top ten brain-protecting foods into your diet. How to cross-train your brain, exercising both the right and left hemisphere. And how to reduce stress, a risk factor for developing dementia and Alzheimer’s, through meditation and 11 other relaxation strategies.

Written by the New York Times bestselling authors of The Memory Bible, this book is...

The Alzheimer's Prevention Cookbook: 100 Recipes to Boost Brain Health

The Alzheimer's Prevention Cookbook: 100 Recipes to Boost Brain Health
by Dr. Marwan Sabbagh (Author), Beau MacMillan (Author)


A full-color cookbook and health guide featuring 100 recipes designed to reduce the risk and delay the onset of Alzheimer's, dementia, and memory loss, for people with a family history of these conditions or those already in the early stages, and their caregivers.

Eat Smart, Stay Sharp

Strong medical evidence suggests that simple changes and additions to your diet can reduce the risk or delay the onset of Alzheimer’s and other forms of dementia and memory loss.

In The Alzheimer’s Prevention Cookbook, Dr. Marwan Sabbagh outlines the latest evidence-based research on Alzheimer’s and nutrition, and presents a dietary plan with nearly 100 recipes to enhance your health. Incorporating high-powered brain-boosting ingredients like turmeric, cinnamon, leafy greens,...

© 2017 BrightSurf.com